SEC Info - Processa Pharmaceuticals, Inc.

SEC Info℠

Home

Help

Please Sign In

Processa Pharmaceuticals, Inc. – ‘8-K’ for 9/7/22

On: Tuesday, 9/6/22, at 9:46pm ET · As of: 9/7/22 · For: 9/7/22 · Accession #: 1493152-22-25171 · File #: 1-39531

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/07/22  Processa Pharmaceuticals, Inc.    8-K:7       9/07/22   11:4.4M                                   M2 Compliance LLC/FA

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     36K 
 2: EX-99.1     Miscellaneous Exhibit                               HTML     21K 
 6: R1          Cover                                               HTML     49K 
 9: XML         IDEA XML File -- Filing Summary                      XML     12K 
 7: XML         XBRL Instance -- form8-k_htm                         XML     15K 
 8: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.LAB  Inline XBRL Taxonomy Extension Label Linkbase        XML     97K 
                Document -- pcsa-20220907_lab                                    
 5: EX-101.PRE  Inline XBRL Taxonomy Extension Presentation          XML     64K 
                Linkbase Document -- pcsa-20220907_pre                           
 3: EX-101.SCH  Inline XBRL Taxonomy Extension Schema Document --    XSD     13K 
                pcsa-20220907                                                    
10: JSON        XBRL Instance as JSON Data -- MetaLinks               25±    34K 
11: ZIP         XBRL Zipped Folder -- 0001493152-22-025171-xbrl      Zip     16K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C: C: C: C: C: C: C:

i 0001533743 i false 0001533743 2022-09-07 2022-09-07 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM i 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): i September 7, 2022

Commission file number i 333-184948

i PROCESSA PHARMACEUTICALS, INC.

(Exact name of Registrant as Specified in its Charter)

i Delaware

i 45-1539785

(State or Other Jurisdiction of

Incorporation or Organization)

(I.R.S. Employer
Identification Number)

i 7380 Coca Cola Drive, i Suite 106, i Hanover, i Maryland i 21076

(Address of Principal Executive Offices, Including Zip Code)

i (443) i 776-3133

(Registrant’s Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

i ☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

i ☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
i Common		i PCSA		i NASDAQ

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. i ☐

Item 7.01. Regulation Disclosure.

A copy of an updated slide presentation (Presentation Materials”) that Processa Pharmaceuticals, Inc. (“Processa Pharmaceuticals”) intends to publish to its website, is attached to this Current Report on Form 8-K and Exhibit 99.1. The Presentation Materials speak as of the date of this Current Report on Form 8-K. While Processa Pharmaceuticals may elect to update the Presentation Materials in the future or reflect events and circumstances occurring or existing after the date of this Current Report on Form 8-K, Processa Pharmaceuticals specifically disclaims any obligation to do so. The information contained in this Item 7.01 and Exhibit 99.1 hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by reference in such a filing.

Exhibit No.		Exhibit Description

99.1		Processa Pharmaceuticals Investor Presentation dated September 2022
104		Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL documents)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized, on September 7, 2022.

	PROCESSA PHARMACEUTICALS, INC.
	Registrant

	By:	/s/ David Young
		David Young
		Chief Executive Officer

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed as of / For Period end:	9/7/22	None on these Dates
Filed on:	9/6/22
		List all Filings

↑Top

Filing Submission 0001493152-22-025171 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)